Prognosis prediction of α-FAtE score for locoregional immunotherapy in hepatocellular carcinoma
Open Access
- 10 January 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1496095
Abstract
Purpose: The α-FAtE score, composed of alpha-fetoprotein, alkaline phosphatase, and eosinophil levels, has been reported as a predictor of prognosis in hepatocellular carcinoma (HCC) patients treated with atezolizumab plus bevacizumab. This study aimed to investigate the predictive ability of α-FAtE score for the efficacy and safety of locoregional immunotherapy as the treatment of HCC patients.Methods and patients: We conducted a retrospective study of 446 HCC patients at Sun Yat-sen University Cancer Center from January 1st 2019 to January 1st 2023. The predictive performance was evaluated by the concordance index, the area under the receiver operating characteristics curve, the Kaplan-Meier curve and multiple Cox regression analysis.Results: 446 patients were divided into the α-FAtE 0-1 group (n=211) and α-FAtE 2-3 group (n=235). The median progression-free survival(PFS) of the α-FAtE 0-1 group and 2-3 group was 7.3 months (95%CI 6.6-8.7 months), and 12.3 months (95% CI 10.4–14.1 months; PP<0.001), respectively. HCC patients in the α-FAtE 2-3 group had higher complete response (CR) rate and experienced less drug-related adverse events than those in the α-FAtE 0-1 group. Moreover, a lower α-FAtE score was identified as an independent prognostic indicator for both OS and PFS of advanced HCC patients receiving locoregional immunotherapy.Conclusion: The α-FAtE score is a superior predictor of prognosis in HCC patients receiving locoregional immunotherapy, offering a valuable tool for patient stratification and treatment planning.Keywords
This publication has 52 references indexed in Scilit:
- Single‐Nucleus and Spatial Transcriptome Profiling Delineates the Multicellular Ecosystem in Hepatocellular Carcinoma After Hepatic Arterial Infusion ChemotherapyAdvanced Science, 2024
- A novel liver-function-indicators-based prognosis signature for patients with hepatocellular carcinoma treated with anti-programmed cell death-1 therapyCancer Immunology, Immunotherapy, 2024
- Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaAnnals of Oncology, 2024
- Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendationsHepatology International, 2023
- Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?Hepatology International, 2023
- Intracranial and Extracranial Progression and Their Correlation With Overall Survival After Stereotactic Radiosurgery in a Multi-institutional Cohort With Brain MetastasesJAMA Network Open, 2023
- IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancerCancer Cell, 2022
- Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trialEuropean Journal of Cancer, 2022
- STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgeryInternational Journal of Surgery, 2021
- Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidenceCancer Treatment Reviews, 2019